TORONTO, May 25, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that it has filed an application with the U.S. Food and Drug Administration (“FDA”) to receive Orphan Drug Designation (“ODD”) for ketamine to treat amyotrophic lateral sclerosis (“ALS”)…

Source

Previous articleHealth Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms
Next articleAdding to their Expert Team, Albert Labs Announces the Formation and Chairs of its Two Advisory Boards